HC Wainwright Issues Pessimistic Forecast for FTH Earnings

Key Points

• HC Wainwright lowered its FY2028 EPS forecast for Sensei Biotherapeutics to a loss of $2.60 per share from $2.37, while maintaining a Buy rating and a $60 price target.
• Despite mixed analyst opinions, Sensei has a consensus Buy rating and an average price target of $56.25; ratings include three Strong Buys, twelve Buys, one Hold, and one Sell.
• Shares opened at $16.83, well below their 52-week high of $42.14. The company reported a quarterly loss of $2.84 per share, beating the consensus estimate for a $5.04 loss.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Free Report) - Equities researchers at HC Wainwright dropped their FY2028 earnings estimates for shares of Sensei Biotherapeutics in a note issued to investors on Thursday, October 22nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($2.60) for the year, down from their previous estimate of ($2.37). HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Sensei Biotherapeutics' current full-year earnings is ($13.69) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics' FY2029 earnings at ($2.61) EPS and FY2030 earnings at ($2.60) EPS.

A number of other research firms have also recently weighed in on FTH. JonesTrading began coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Guggenheim assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They set a "buy" rating and a $70.00 price target for the company. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a "buy" rating and a $56.00 price target for the company. Finally, Citizens Jmp initiated coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an "outperform" rating and a $51.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $56.25.

Sensei Biotherapeutics Price Performance

Shares of FTH stock opened at $16.83 on Tuesday. The firm has a 50-day moving average of $29.91. The firm has a market cap of $434.89 million, a PE ratio of -0.12 and a beta of -0.29. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of large investors have recently modified their holdings of FTH. Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics during the second quarter worth $307,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics in the second quarter valued at $3,610,000. Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the first quarter valued at $22,758,000. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth $4,188,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei's pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company's ImmunoPhage platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.